Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2021; 27(23): 3238-3248
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3238
Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis
Tasur Kumar Seen, Muntazir Sayed, Muhammad Bilal, Jonathan Vincent Reyes, Priyanka Bhandari, Vennis Lourdusamy, Ahmed Al-khazraji, Umer Syed, Yasar Sattar, Raghav Bansal
Tasur Kumar Seen, Jonathan Vincent Reyes, Priyanka Bhandari, Yasar Sattar, Division of Internal Medicine, Icahn School of Medicine, Elmhurst Hospital and Mount Sinai Hospital, Elmhurst, NY 11375, United States
Muntazir Sayed, Division of Internal Medicine, R.C.S.M. Government College, Mahrashta 416013, India
Muhammad Bilal, Division of Gastroenterology, Hepatology and Endoscopy, Pakistan Institute of Medical Sciences, Islamabad 45710, Pakistan
Vennis Lourdusamy, Ahmed Al-khazraji, Umer Syed, Division of Gastroenterology, Icahn School of Medicine, Elmhurst Hospital and Mount Sinai Hospital, Elmhurst, NY 11375, United States
Raghav Bansal, Division of Gastroenterology, Icahn School of Medicine, Elmhurst Hospital, Elmhurst, NY 11375, United States
Author contributions: Seen TK wrote the final versions of the manuscript and did the final editing; Al Khazraji A, Lourdusamy V, Reyes JV and Bansal R assisted with the final editing; Reyes JV, Sayed M and Bilal M conducted the literature search and edited the original versions of the manuscript; Bhandari P, Syed U and Sattar Y conceived of the manuscript and wrote the first versions of the manuscript.
Conflict-of-interest statement: No individuals or any associated parties have any conflicts-of-interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed Al-khazraji, MD, Academic Fellow, Division of Gastroenterology, Icahn School of Medicine, Elmhurst Hospital and Mount Sinai Hospital, 79-01 Broadway, Elmhurst, NY 11375, United States. alkhazra@nychhc.org
Received: October 24, 2020
Peer-review started: October 24, 2020
First decision: November 25, 2020
Revised: December 6, 2020
Accepted: April 20, 2021
Article in press: April 20, 2021
Published online: June 21, 2021
Core Tip

Core Tip: Fatty liver disease rates along with obesity, diabetes and metabolic syndrome continue to increase and now is the second leading cause of cirrhosis secondary to alcohol related liver disease. The need for consistent and readily available methods to accurately diagnose and stage hepatic fibrosis becomes increasingly necessary. With an up to date armamentarium to diagnose and treat the full spectrum of non-alcoholic fatty liver disease will decrease complications such as cirrhosis and hepatocellular carcinoma and will improve the likelihood for patients to have a higher quality of life.